Paper41923909
The effects of Panax notoginseng for the treatment of diabetic nephropathy in animals: a systematic review and meta-analysis.
Liu J and 8 others. Front Nutr, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The effects of Panax notoginseng for the treatment of diabetic nephropathy in animals: a systematic review and meta-analysis. Papers, record 41923909. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41923909
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The effects of Panax notoginseng for the treatment of diabetic nephropathy in animals: a systematic review and meta-analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34360646 | TGF-Beta as a Master Regulator of Diabetic Nephropathy. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34360646 | PubMed |
| 2 | 36375645 | Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice. | J Ethnopharmacol | 2023 | https://conductscience.org/library/papers/36375645 | PubMed |
| 3 | 26429402 | Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. | Lancet Diabetes Endocrinol | 2015 | https://conductscience.org/library/papers/26429402 | PubMed |
| 4 | 25691433 | Standard deviation or the standard error of the mean. | BMJ | 2015 | https://conductscience.org/library/papers/25691433 | PubMed |
| 5 | 36202661 | Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). | Kidney Int | 2022 | https://conductscience.org/library/papers/36202661 | PubMed |
| 6 | 36699083 | Effectiveness and safety of selected traditional Chinese medicine injections in patients with combined diabetes mellitus and coronary heart disease: A systematic review and network meta-analysis of randomized clinical trials. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36699083 | PubMed |
| 7 | 36830828 | Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update. | Biomedicines | 2023 | https://conductscience.org/library/papers/36830828 | PubMed |
| 8 | 39380993 | The Nrf2-HO-1 system and inflammaging. | Front Immunol | 2024 | https://conductscience.org/library/papers/39380993 | PubMed |
| 9 | 35089525 | Acute Developmental Toxicity of Panax notoginseng in Zebrafish Larvae. | Chin J Integr Med | 2023 | https://conductscience.org/library/papers/35089525 | PubMed |
| 10 | 30634720 | Notoginsenoside R1 Protects db/db Mice against Diabetic Nephropathy via Upregulation of Nrf2-Mediated HO-1 Expression. | Molecules | 2019 | https://conductscience.org/library/papers/30634720 | PubMed |
| 11 | 39806549 | Trends and analysis of risk factor differences in the global burden of chronic kidney disease due to type 2 diabetes from 1990 to 2021: A population-based study. | Diabetes Obes Metab | 2025 | https://conductscience.org/library/papers/39806549 | PubMed |
| 12 | 28634988 | Panax notoginseng Preparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis. | Phytother Res | 2017 | https://conductscience.org/library/papers/28634988 | PubMed |
| 13 | 30425453 | Combination of Ginsenoside Rg1 and Astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy. | Drug Des Devel Ther | 2018 | https://conductscience.org/library/papers/30425453 | PubMed |
| 14 | 39307799 | [Mechanism of Panax notoginseng saponins in treating diabetic kidney disease based on network pharmacology and experimental verification]. | Zhongguo Zhong Yao Za Zhi | 2024 | https://conductscience.org/library/papers/39307799 | PubMed |
| 15 | 33782057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
| 16 | 36064360 | The efficacy and safety of the Xuesaitong soft capsule in the treatment of patients with ischemic stroke: systematic review and meta-analysis. | Ann Palliat Med | 2022 | https://conductscience.org/library/papers/36064360 | PubMed |
| 17 | 32051833 | Xuesaitong Protects Podocytes from Apoptosis in Diabetic Rats through Modulating PTEN-PDK1-Akt-mTOR Pathway. | J Diabetes Res | 2020 | https://conductscience.org/library/papers/32051833 | PubMed |
| 18 | 37745069 | Antioxidant and anti-inflammatory properties of ginsenoside Rg1 for hyperglycemia in type 2 diabetes mellitus: systematic reviews and meta-analyses of animal studies. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37745069 | PubMed |
| 19 | 40852615 | Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40852615 | PubMed |
| 20 | 32471207 | Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32471207 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42948596 | Global research trends in clinical studies of ginseng: a bibliometric and text-as-data analysis. | J Ginseng Res | 2026 | https://conductscience.org/library/papers/42948596 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41923909
GET https://conductscience.org/api/papers/v1/41923909/references?page=2